<H1>Chapter DOI: 10.1007/s00105-015-3590-4<br/>Cited-By Count: 2</H1><table border="1" width="30%"><tr><td>Total References</td><td>7</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>7</td></tr><tr><td>BibStructured Count</td><td width="10%">6</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>6</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507&#8211;2516</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1103782>10.1056/NEJMoa1103782</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J (2013) Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 27(1):11&#8211;18</td><td><a href=http://dx.doi.org/10.1111/j.1468-3083.2012.04546.x>10.1111/j.1468-3083.2012.04546.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611&#8211;621</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2013.11.002>10.1016/j.ejca.2013.11.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Minor DR, Rodvien R, Kashani-Sabet M (2012) Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res 22(5):410&#8211;411</td><td><a href=http://dx.doi.org/10.1097/CMR.0b013e3283573437>10.1097/CMR.0b013e3283573437</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wantz</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Spanoudi-Kitrimi</span> <span style='background:#DDDDDD'>I</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lasek</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lebas</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Quinchon</span> <span style='background:#DDDDDD'>J-F</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Modiano</span> <span style='background:#DDDDDD'>P</span></span></aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>[Vemurafenib-induced toxic epidermal necrolysis]</span>. <span style='background:#CCFF99'>Ann Dermatol Venereol</span> <span style='background:#FFCC66'>141</span>(<span style='background:#C8BE84'>3</span>):<span style='background:#D279FF'>215&#8211;218</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Farnam K, Chang C, Teuber S, Gershwin ME (2012) Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol 159(4):327&#8211;345</td><td><a href=http://dx.doi.org/10.1159/000339690>10.1159/000339690</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A et al (2010) General considerations on rapid desensitization for drug hypersensitivity &#8211; a consensus statement. Allergy 65(11):1357&#8211;1366</td><td><a href=http://dx.doi.org/10.1111/j.1398-9995.2010.02441.x>10.1111/j.1398-9995.2010.02441.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>